In 2011 the American Association for the Study of Liver Diseases released "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection" this month a new section was added to the guidelines entitled "Use and Interpretation of HCV RNA Results During Triple Therapy."
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Monday, January 14, 2013
Updated Practice Guideline: Treatment of Genotype 1 Chronic HCV Virus Infection
In 2011 the American Association for the Study of Liver Diseases released "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection" this month a new section was added to the guidelines entitled "Use and Interpretation of HCV RNA Results During Triple Therapy."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment